Трудности и пути их преодоления при подборе терапии болевых синдромов у больных сахарным диабетом
https://doi.org/10.33667/2078-5631-2021-22-25-30
Аннотация
Сахарный диабет (СД) вызывает повреждение различных систем организма, в том числе, периферической нервной системы. Рассматриваются основные варианты поражения периферических нервов при СД. Приводятся сведения о развитии такого рода поражения, в частности, о формировании нейропатического болевого синдрома. Анализируются терапевтические возможности препаратов из различных фармакологических групп для лечения пациентов с неврологическими осложнениями СД.
Об авторах
К. А. Махинов
АО «Европейский медицинский центр»
Россия
Россия
Махинов Константин Алексеевич, врач-невролог
Москва
П. Р. Камчатнов
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава
России
Россия
Россия
Камчатнов Павел Рудольфович, д.м.н., проф. кафедры неврологии, нейрохирургии и медицинской генетики
Москва
Список литературы
1. Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017; 20 (1): 13–41. DOI: 10.14341/DM8664.
2. Guariguata L., Whiting D. R., Hambleton I. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014 Feb; 103 (2): 137–49. DOI: 10.1016/j.diabres.2013.11.002.
3. International Association for the study of Pain. IASP Terminology – IASP [Internet]. www.iasppain.org/terminology? Accessed 4 Oct 2020.
4. Кукушкин М.Л., Яхно Н.Н., Чурюканов М.В. и соавт. Ноципластическая боль – новый дескриптор или упрощенный взгляд на проблему боли? Российский журнал боли. 2018; 2: 268–270.
5. Busui R.P., Boulton A.J.M., Feldman E.L. et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association Diabetes Care 2017; 40: 136–154. DOI: 10.2337/dc16–2042.
6. Stierli S., Imperatore V., Lloyd A. Schwann cell plasticity–roles in tissue homeostasis, regeneration, and disease. Glia. 2019 Nov; 67 (11): 2203–2215. DOI: 10.1002/glia.23643.
7. Callaghan B., Cheng H., Stables C., et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012; 11: 521. DOI: 10.1016/S1474–4422(12)70065–0.
8. Ritzwoller DP, Ellis JL, Korner EJ, Hartsfeld CL, Sadosky A. Comorbidities, healthcare service utilization and costs for patients identifed with painful DPN in a managed-care setting. Curr Med Res Opin. 2009 Jun; 25 (6): 1319–28. DOI: 10.1185/03007990902864749.
9. Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diab Rep. 2012 Aug; 12 (4): 376–83. DOI: 10.1007/s11892–012–0278–3.
10. Ziegler D., Hanefeld M., Ruhnau K. et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant lipoic acid. Diabetologia. 1995; 38 (12): 1425–33. DOI: 10.1007/BF00400603.
11. Ziegler D., Ametov A., Barinov A. et al. Oral treatment with lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY2 trial. Diabetes Care. 2006; 29 (11): 2365–70. DOI: 10.2337/dc06–1216.
12. Ziegler D, Nowak H, Kempler P. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004; 21 (2): 114–121. DOI: 10.1111/j.1464–5491.2004.01109.x
13. Mijnhout G., Kollen B., Alkhalaf A. et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012; 2012: 456279; DOI: 10.1155/2012/456279.
14. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev. 2006; 11: 294–329.
15. Ang C., Alviar M., Dans L. et al. Vitamin B for treating peripheral neuropathy. Cochrane Database Syst Rev. 2008 Jul 16; (3): CD004573. DOI: 10.1002/14651858.CD004573.pub3.
16. Sawangjit R., Thongphui S., Chaichompu W., Phumart P. Effcacy and Safety of Mecobalamin on Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Altern Complement Med. 2020. Dec; 26 (12): 1117–1129. DOI: 10.1089/acm.2020.0068. Epub 2020 Jul 21.
17. Karaganis S., Song X. B vitamins as a treatment for diabetic pain and neuropathy. J Clin Pharm Ther. 2021 Feb 9. DOI: 10.1111/jcpt.13375. Online ahead of print.
18. Finnerup N.B., Attal N., Haroutounian S. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb; 14 (2): 162–73. DOI: 10.1016/S1474–4422(14)70251–0.
19. Камчатнов П.Р., Евзельман М.А., Абусуева Б.А., Волков А.И. Капсаицин в лечении нейропатической боли. Журнал неврологии и психиатрии им. C.C. Корсакова. 2014; 114 (11): 135–144.
20. Mason L., Moore R., Derry S. et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004; 328 (7446): 991. DOI: 10.1136/bmj.38042.506748.EE.
21. Bril V., England J., Franklin GM. et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011 May 17; 76 (20): 1758–65. DOI: 10.1212/WNL.0b013e3182166ebe.
22. Argoff C., Galer BS, Jensen M. et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the neuropathic pain scale. Curr Med Res Opin. 2004;20 Suppl 2: S21–S8. DOI: 10.1185/030079904X12960.
23. Barbano RL, Herrmann DN, Hart-Gouleau S. et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004; 61 (6): 914–8. DOI: 10.1001/archneur.61.6.914.
24. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis. 2001; 3 (2): 53–62. DOI: 10.1097/00131402–200112000–00002.
25. Gilron I., Bailey J., Tu D. et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. Lancet. 2010; 374 (9697): 1252–61. DOI: 10.1016/S0140–6736(09)61081–3.
26. Bouhassira D., Wilhelm S., Schacht A. et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain. 2014 Oct; 155 (10): 2171–9. DOI: 10.1016/j.pain.2014.08.020.
27. Yuan R., Sheu J., Yu J. et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009; 72: 1473–8. DOI: 10.1212/01.wnl.0000345968.05959.cf.
28. Chen W., Yuan R., Chiang S. et al. Onabotulinumtoxin A improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain. 2013; 29: 305–10. DOI: 10.1097/AJP.0b013e318255c132.
29. Provenzano D., Heller J., Hanes M. Current Perspectives on Neurostimulation for the Management of Chronic Low Back Pain: A Narrative Review. J Pain Res. 2021 Feb 17; 14: 463–479. DOI: 10.2147/JPR.S249580.
30. Taylor R., van Buyten J., Buscher E. Spinal cord stimulation for chronic back and leg pain and failed back surgery syndrome: a systematic review and analysis of prognostic factors. Spine. 2005; 30: 152–60. DOI: 10.1097/01.brs.0000149199.68381.fe.
31. Abate M., Di Carlo L., Salini V., Schiavone C. Metabolic syndrome associated to non-inflammatory Achilles enthesopathy. Clin Rhuematol. 2014; 33: 1517–1522. DOI: 10.1007/s10067–014–2524–3.
32. Wise B., Peloquin C., Choi H. et al. 2012; 125: 1228.e23–1228.e28. DOI: 10.1016/j.amjmed.2012.05.027.
33. Papachristou S, Pafli K, Papanas N. Skin AGEs and diabetic neuropathy. BMC Endocr Disord. 2021 Feb 23; 21 (1): 28. DOI: 10.1186/s12902–021–00697–7.
34. Dhumad M., Hamdan F., Khudhair M., Al-Matubsi H. Correlation of staging and risk factors with cardiovascular autonomic neuropathy in patients with type II diabetes mellitus. Sci Rep. 2021 Feb 11; 11 (1): 3576. DOI: 10.1038/s41598–021–80962-w.
35. Moon S., Kim C., Kang S. et al. Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015). Diabetes Metab J. 2021 Jan; 45 (1): 115–119. DOI: 10.4093/dmj.2020.0120.
36. Freeman R. Diabetic autonomic neuropathy. Handb Clin Neurol 2014; 126: 63–79. DOI: 10.1016/B978–0–444–53480–4.00006–0.
37. Jones K., Russo A., Stevens J. et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001; 24 (7): 1264–1269. DOI: 10.2337/diacare. 24.7.1264.
38. Camilleri M. Gastrointestinal motility disorders in neurologic disease. J Clin Invest.2021 Feb 15; 131 (4): e143771. DOI: 10.1172/JCI143771.
39. Marathe C., Jones K., Wu T. et al. Gastrointestinal autonomic neuropathy in diabetes. Auton Neurosci. 2020 Dec; 229: 102718. DOI: 10.1016/j.autneu.2020.102718.
40. Kuźnik E., Dudkowiak R., Adamiec R., Poniewierka E. Diabetic autonomic neuropathy of the gastrointestinal tract. Prz Gastroenterol. 2020; 15 (2): 89–93. DOI: 10.5114/pg.2020.95554.
Рецензия
Для цитирования:
Махинов К.А., Камчатнов П.Р. Трудности и пути их преодоления при подборе терапии болевых синдромов у больных сахарным диабетом. Медицинский алфавит. 2021;(22):25-30. https://doi.org/10.33667/2078-5631-2021-22-25-30
For citation:
Makhinov K.A., Kamchatnov P.R. Diffculties and ways to overcome them in selection of therapy for pain syndromes in patients with diabetes mellitus. Medical alphabet. 2021;(22):25-30. (In Russ.) https://doi.org/10.33667/2078-5631-2021-22-25-30
Просмотров:
238
Послать статью по эл. почте 